Radiopharm Theranostics (RADX) Total Liabilities (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Total Liabilities for 2 consecutive years, with $43.6 million as the latest value for Q2 2025.
- On a quarterly basis, Total Liabilities fell 2.4% to $43.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $43.6 million, a 2.4% decrease, with the full-year FY2025 number at $43.6 million, down 2.4% from a year prior.
- Total Liabilities was $43.6 million for Q2 2025 at Radiopharm Theranostics, down from $44.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $44.7 million in Q2 2024 to a low of $43.6 million in Q2 2025.